Orionis is a clinical-stage life sciences company developing conditionally acting medicines for cancer and other diseases. Our pipeline includes targeted cytokine immunotherapies and molecular glue drug modalities.
Pioneering technology. Leveraging molecular proximity and cooperativity mechanisms in drug action
Diversified product pipeline. Restarting a stalled cancer immunity cycle
Clinical trials. First-in-class reprogrammed interferon cytokine (ORB-011) in Phase 1 for patients with solid tumors
Powerful collaborations. Partners include Novartis and Genentech
Learn about our approach.
Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011 in Patients with Advanced Solid Tumors
Controlled immune system activation
A-Kines are cytokine-based biologics with in vivo cell target selectivity vastly superior to traditional cytokine modalities.
A-Kines represent a new drug modality, but also incorporate, while somewhat modified, commonly used molecular building blocks used across other types of biologics. These impart desired pharmacological, manufacturing, and clinical application characteristics.
Allosteric molecular glues
Allo-Glues are monovalent, drug-like small molecules that act in unique fashion to provide access to historically undruggable and new disease targets, inhibiting or promoting their degradation by invoking nature’s cellular protein disposal machineries.
Our technology solutions enable a scaled, target-agnostic, plug-and-play approach to discovery, optimization, and rational design of molecular glues for high value disease targets.
Pioneering technology. Leveraging molecular proximity and cooperativity mechanisms in drug action
Diversified product pipeline. Restarting a stalled cancer immunity cycle
Clinical trials. First-in-class reprogrammed interferon cytokine (ORB-011) in Phase 1 for patients with solid tumors
Powerful collaborations. Partners include Novartis and Genentech
Learn about our approach.
November 15, 2023
Controlled immune system activation
A-Kines are cytokine-based biologics with in vivo cell target selectivity vastly superior to traditional cytokine modalities.
A-Kines represent a new drug modality, but also incorporate, while somewhat modified, commonly used molecular building blocks used across other types of biologics. These impart desired pharmacological, manufacturing, and clinical application characteristics.
Learn moreAllosteric molecular glues
Allo-Glues are monovalent, drug-like small molecules that act in unique fashion to provide access to historically undruggable and new disease targets, inhibiting or promoting their degradation by invoking nature’s cellular protein disposal machineries.
Our technology solutions enable a scaled, target-agnostic, plug-and-play approach to discovery, optimization, and rational design of molecular glues for high value disease targets.
Learn more